2022 ASH Poster Presentation
Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies2021 ASH Abstract
Clinical Manufacture of FT819: Use of a Clonal Multiplexed-Engineered Master Induced Pluripotent Stem Cell Line to Mass Produce Off-the-Shelf CAR T-Cell Therapy2019 ASH Abstract
FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical TrialNature Medicine. 2019; 25: 82–88.
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency2022 ASH Poster Presentation
2022 SITC Poster Presentation
2022 AACR Posters
2022 ASGCT Posters
2021 SITC Abstract
2021 ASH Abstract
Stem Cell Report